Updated: GSK taps Chinese partner to ramp up Shingrix sales in $3.05B deal, with option to expand to RSV
GSK is tapping a heavyweight partner to co-promote its blockbuster shingles vaccine Shingrix in China — and locking in £2.5 billion ($3.05 billion) over the next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.